Taylor Wealth Management Partners Buys 6,316 Shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Taylor Wealth Management Partners raised its stake in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 9.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 70,637 shares of the company’s stock after purchasing an additional 6,316 shares during the period. Taylor Wealth Management Partners’ holdings in Global Blood Therapeutics were worth $2,878,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GBT. Artisan Partners Limited Partnership bought a new position in shares of Global Blood Therapeutics in the 4th quarter valued at about $34,728,000. Norges Bank bought a new position in shares of Global Blood Therapeutics in the 4th quarter valued at about $24,006,000. Janus Henderson Group PLC lifted its holdings in shares of Global Blood Therapeutics by 10.0% in the 4th quarter. Janus Henderson Group PLC now owns 5,966,862 shares of the company’s stock valued at $258,426,000 after acquiring an additional 540,580 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Global Blood Therapeutics by 11.1% in the 4th quarter. BlackRock Inc. now owns 3,683,260 shares of the company’s stock valued at $159,522,000 after acquiring an additional 367,275 shares during the last quarter. Finally, Voloridge Investment Management LLC lifted its holdings in shares of Global Blood Therapeutics by 1,041.4% in the 4th quarter. Voloridge Investment Management LLC now owns 341,583 shares of the company’s stock valued at $14,794,000 after acquiring an additional 311,657 shares during the last quarter.

Shares of NASDAQ:GBT traded down $1.01 during trading on Friday, reaching $42.15. 3,665 shares of the company were exchanged, compared to its average volume of 971,299. The firm has a market capitalization of $2.62 billion, a PE ratio of -9.35 and a beta of 1.39. The business’s fifty day simple moving average is $41.78 and its 200-day simple moving average is $46.73. Global Blood Therapeutics, Inc. has a 12-month low of $36.49 and a 12-month high of $83.69. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.63 and a quick ratio of 7.20.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Tuesday, February 23rd. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.03). Global Blood Therapeutics had a negative net margin of 332.94% and a negative return on equity of 56.43%. The business had revenue of $41.30 million for the quarter, compared to the consensus estimate of $38.89 million. On average, sell-side analysts anticipate that Global Blood Therapeutics, Inc. will post -3.98 EPS for the current fiscal year.

A number of brokerages recently commented on GBT. Zacks Investment Research raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating and set a $45.00 price target for the company in a report on Tuesday, April 6th. William Blair downgraded shares of Global Blood Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, February 25th. SVB Leerink initiated coverage on shares of Global Blood Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $54.00 price objective on the stock. Wolfe Research initiated coverage on shares of Global Blood Therapeutics in a research report on Wednesday, March 17th. They issued an “outperform” rating and a $67.00 price objective on the stock. Finally, Piper Sandler lowered shares of Global Blood Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $75.00 to $50.00 in a research report on Wednesday, January 20th. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $88.05.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD.

Further Reading: Trading on Margin

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.